Business
Milestone Pharmaceuticals enrolls first Canadian patient in AFib Phase 3 trial
The biotech's etripamil nasal spray moves into a 150-patient Phase 3 study for atrial fibrillation with rapid ventricular rate, pursued via a single-study NDA pathway.
MDpanel Appoints Manish Nariwal as COO and Jim Andrews as Chief Client Officer
MDpanel announced the appointment of Manish Nariwal as COO and Jim Andrews as chief client officer to oversee operations and client relations, with both reporting to CEO Jason Erdell.
Tvardi reports preclinical STAT3 inhibitor data for colitis
Tvardi Therapeutics published data showing its STAT3 inhibitors prevented colon tumors in a colitis-associated cancer mouse model, bolstering the pipeline ahead of planned GI clinical trials.
Absci Plans Mid-2027 Phase 2 Trial of Endometriosis Drug ABS-201
The clinical-stage biopharmaceutical plans a dose-ranging study of its AI-engineered anti-prolactin receptor antibody in roughly 150 patients.
Rockwell Automation Announces Leadership Changes Effective October 1, 2026
The company said Tessa Myers will become senior vice president and chief revenue officer, succeeding Scott Genereux who plans to retire at year‑end 2026. Matt Fordenwalt moves to lead Intelligent Devices and Jordan Reynolds takes over Lifecycle Services.
EU Delays Vote on Tesla's Supervised Self-Driving System, Next Chance in December
The European Union’s Technical Committee on Motor Vehicles postponed a decision on Tesla’s Full Self‑Driving (Supervised) system from an October 6 vote to its December meeting, leaving approval pending amid mixed national clearance and safety‑data scrutiny.
1875 Finance appoints Peter Raskin as Director for Zurich Private Banking
Independent wealth manager 1875 Finance announces the appointment of Peter Raskin, former CEO of Berenberg Schweiz and Bergos, to expand its private banking business in Zurich.
Lisata to Present MAR001 Phase 2b Trial Data at AHA Conference
Marea Therapeutics, a Lisata subsidiary, will report late-breaking results from its TYDAL study on ANGPTL4 inhibition at the American Heart Association Scientific Sessions in Chicago.
Lakewood-Amedex begins Phase 2a trial of Nu-3 gel for diabetic foot ulcers
Lakewood-Amedex Biotherapeutics dosed its first patient in a Phase 2a, single‑blind, dose‑finding study of Nu‑3, a topical antimicrobial gel, in mildly infected diabetic foot ulcers. Topline data are expected in Q1 2027.
Lowe’s Begins Drone Delivery Pilot in Matthews, North Carolina
The home‑improvement retailer is testing a drone service with Wing and DoorDash that can deliver small items in as little as 20 minutes from its Matthews store. Eligible products include hand tools, paint, cleaning supplies and batteries.
Mobix Labs Forecasts Q4 Revenue Above Guidance Midpoint
The Irvine-based electronic components maker expects fourth-quarter 2026 revenue to exceed $1.6 million, surpassing the midpoint of its prior $1.4‑$1.8 million range, driven by stronger wireless systems and defense demand.
Revvity launches type 1 diabetes screening kit across Europe
The CE-IVDR-certified GSP T1D 3plex kit enables population-wide screening for at-risk children months or years before symptoms appear.
Ensysce Submits Phase 2a Protocol for CRPS Drug CY200 to UK Regulator
The San Diego-based biotech filed its CYBIO_001 protocol with the MHRA for a trial of CY200 in Complex Regional Pain Syndrome Type 1, acquired from Cy Biopharma.
RockawayX Bets $150 Million That Onchain Yield Will Be Crypto's Next Big Use Case
The $2 billion digital-asset firm launches Catapult to back private credit and other yield-generating real-world assets onchain, projecting a $10T–$20T market by 2030.
Partners Group Gets EU Approval for Aroma-Zone Acquisition
Swiss PE firm receives clearance to buy majority stake in French natural cosmetics brand from Eurazeo; deal valued at roughly €2 billion.
Starbucks to close 250 unprofitable stores in North America
The coffee chain is winding down a second round of restructuring, with about $300 million in costs expected, while cutting its global store-opening target to roughly 440.
Verastem to Share Ovarian Cancer Trial Data at Montreal Conference
Verastem Oncology will present phase 2 data on its avutometinib-plus-defactinib combo for low-grade serous ovarian cancer at the IGCS annual meeting.
Oracle Health Teams With ID.me to Add Digital ID Verification to Healthcare Platform
The partnership integrates ID.me’s reusable digital wallets into Oracle Health’s systems to streamline patient intake and verify prescriber credentials for controlled substances, covering ID.me’s network of nearly five million medical professionals and over 175 million users.
SEALSQ's VaultIC408 earns FIPS 140‑3 Level 3 validation
The Geneva‑based firm’s VaultIC408 secure element received FIPS 140‑3 Level 3 certification from NIST, valid through August 2031.
Schroder Asian Total Return Completes Merger with Pacific Assets Trust
The investment trust issued over 52 million new shares to acquire Pacific Assets Trust’s net assets, boosting its net assets to roughly £1 billion and reducing its ongoing management fee.
Taoping wins $5.5 million in smart elevator orders in China
The NASDAQ‑listed firm’s subsidiary Skyladder secured contracts for smart‑elevator modernization projects, aligning with China’s plan to upgrade 575,000 residential lifts during the 15th Five‑Year Plan.
Elmet Acquires 4.99% Stake in Masan High-Tech Materials for $2.5B Valuation
The Elmet Group takes a nearly 5% stake in Vietnam's Masan High-Tech Materials alongside an eight-year, $1.5B tungsten supply deal, valuing the miner at $2.5 billion.
Uxin Q2 2026 Revenue Surges 75% YoY, Stock Climbs 11% in Premarket
The Chinese used‑car platform reported CNY 1.151 billion in revenue for the quarter ended June 30 2026, driven by an 89% jump in retail vehicle transactions, while its shares rose 11.14% to $1.211 in premarket trade.
BCE Outlines AI, Fiber Growth Targets at CIBC Investor Conference
The telecom group said it aims to cut net debt leverage to 3.5 times by end‑2027 and generate up to CAD 2 billion in AI‑powered revenue by 2028, while raising its AI‑fabric power guidance to 373 megawatts.
Pasqal posts 14% revenue rise in H1 2026 as operating loss widens
The quantum‑computing firm reported EUR 4.9 million revenue, up 14% YoY, while operating loss grew to EUR 59.2 million; cash balances rose to EUR 110.8 million and shares slipped 2.3% pre‑market.
